Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

By | July 12, 2021
Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern.